SS-31

SS-31 — elamipretide — is the only peptide in this catalog whose mechanism is defined not by a receptor but by a phospholipid. Hazel Szeto and Peter Schiller at Cornell developed the compound in the early 2000s as part of a series of aromatic-cationic tetrapeptides designed to concentrate in the inner mitochondrial membrane. Their guiding observation was that the membrane's characteristic negative charge, and the presence of cardiolipin — a signature phospholipid found only there — created a chemical opportunity: a small peptide with the right pattern of positive charges and aromatic residues would accumulate against the electrical gradient into the exact place where mitochondria run their energy machinery. The Szeto-Schiller peptides (SS-01, SS-02, SS-20, SS-31) each did that; SS-31 became the clinical candidate because it combined tight cardiolipin binding, chemical stability, and a clean tolerability profile.

The chemistry is deceptively simple: four amino acids, one of them a modified tyrosine (2',6'-dimethyl-Tyr) that gives the molecule its distinctive interaction with the phospholipid bilayer, and a D-arginine and a lysine that carry the net positive charge required for mitochondrial-inner-membrane concentration. The compound accumulates in the inner membrane at roughly a thousandfold higher concentration than in cytoplasm. Once there it binds cardiolipin, and cardiolipin — because it holds the electron-transport-chain complexes in their working supercomplex arrangement and stabilises cristae architecture — is the load-bearing point for the whole downstream cascade. Stabilising cardiolipin restores efficient ATP synthesis, reduces electron leak into reactive-oxygen-species, and preserves the cristae shape that mitochondria need to function.

The clinical development story belongs to Stealth BioTherapeutics, which licensed the Szeto peptides and organised the programme around Barth syndrome — an X-linked disorder of TAZ (tafazzin), the enzyme that remodels cardiolipin acyl chains. In Barth syndrome the mitochondrial cardiolipin pool is malformed, cristae are disorganised, and patients present in infancy with cardiomyopathy, skeletal muscle weakness, neutropenia and growth failure. The Stealth pivotal trial TAZPOWER (Reid Thompson et al. Genetics in Medicine 2021) was a randomised placebo-controlled crossover in Barth syndrome patients; its extension (TAZPOWER-2) showed durable improvements in knee-extensor strength and six-minute-walk distance. Elamipretide subsequently received FDA approval for Barth syndrome under the trade name Forzinity — an unusual pharmaceutical-approval outcome for a small research peptide.

The broader mitochondrial-medicine ambitions of the programme have not all succeeded. MMPOWER-3, the phase-3 trial in primary mitochondrial myopathy, did not meet its primary six-minute-walk-distance endpoint. Earlier acute-cardiac programmes (EMBRACE STEMI in ST-elevation myocardial infarction, MEND2 in heart failure) were discontinued after negative outcomes. A dry age-related macular degeneration programme (ReCLAIM and ReCLAIM-2) has produced some signal on retinal photoreceptor function but has not yet delivered a definitive positive phase-3 result. That mixed record is important context: elamipretide is a real drug with a real mechanism and one real approved indication — not a general 'mitochondrial rejuvenator'. Consumer-facing descriptions that generalise from the Barth approval to broader anti-ageing claims are running well beyond the evidence.

SS-31 — elamipretide — is the only peptide in this catalog whose mechanism is defined not by a receptor but by a phospholipid. Hazel Szeto and Peter Schiller at Cornell developed the compound in the early 2000s as part of a series of aromatic-cationic tetrapeptides designed to concentrate in the inner mitochondrial membrane. Their guiding observation was that the membrane's characteristic negative charge, and the presence of cardiolipin — a signature phospholipid found only there — created a chemical opportunity: a small peptide with the right pattern of positive charges and aromatic residues would accumulate against the electrical gradient into the exact place where mitochondria run their energy machinery. The Szeto-Schiller peptides (SS-01, SS-02, SS-20, SS-31) each did that; SS-31 became the clinical candidate because it combined tight cardiolipin binding, chemical stability, and a clean tolerability profile.

The chemistry is deceptively simple: four amino acids, one of them a modified tyrosine (2',6'-dimethyl-Tyr) that gives the molecule its distinctive interaction with the phospholipid bilayer, and a D-arginine and a lysine that carry the net positive charge required for mitochondrial-inner-membrane concentration. The compound accumulates in the inner membrane at roughly a thousandfold higher concentration than in cytoplasm. Once there it binds cardiolipin, and cardiolipin — because it holds the electron-transport-chain complexes in their working supercomplex arrangement and stabilises cristae architecture — is the load-bearing point for the whole downstream cascade. Stabilising cardiolipin restores efficient ATP synthesis, reduces electron leak into reactive-oxygen-species, and preserves the cristae shape that mitochondria need to function.

The clinical development story belongs to Stealth BioTherapeutics, which licensed the Szeto peptides and organised the programme around Barth syndrome — an X-linked disorder of TAZ (tafazzin), the enzyme that remodels cardiolipin acyl chains. In Barth syndrome the mitochondrial cardiolipin pool is malformed, cristae are disorganised, and patients present in infancy with cardiomyopathy, skeletal muscle weakness, neutropenia and growth failure. The Stealth pivotal trial TAZPOWER (Reid Thompson et al. Genetics in Medicine 2021) was a randomised placebo-controlled crossover in Barth syndrome patients; its extension (TAZPOWER-2) showed durable improvements in knee-extensor strength and six-minute-walk distance. Elamipretide subsequently received FDA approval for Barth syndrome under the trade name Forzinity — an unusual pharmaceutical-approval outcome for a small research peptide.

The broader mitochondrial-medicine ambitions of the programme have not all succeeded. MMPOWER-3, the phase-3 trial in primary mitochondrial myopathy, did not meet its primary six-minute-walk-distance endpoint. Earlier acute-cardiac programmes (EMBRACE STEMI in ST-elevation myocardial infarction, MEND2 in heart failure) were discontinued after negative outcomes. A dry age-related macular degeneration programme (ReCLAIM and ReCLAIM-2) has produced some signal on retinal photoreceptor function but has not yet delivered a definitive positive phase-3 result. That mixed record is important context: elamipretide is a real drug with a real mechanism and one real approved indication — not a general 'mitochondrial rejuvenator'. Consumer-facing descriptions that generalise from the Barth approval to broader anti-ageing claims are running well beyond the evidence.

The mechanistic foundation for elamipretide is the Szeto laboratory's characterisation of the Szeto-Schiller peptide series. The 2011 Szeto review lays out the design principles — aromatic-cationic tetrapeptides that concentrate against the electrical gradient into the inner mitochondrial membrane, where the specific composition of cardiolipin binds them. Birk et al. 2013 (Journal of the American Society of Nephrology) is one of the important secondary references showing that elamipretide binds cardiolipin directly and preserves cristae architecture in kidney ischaemia-reperfusion models.

TAZPOWER (Reid Thompson et al. Genetics in Medicine 2021) is the pivotal Barth-syndrome trial. It was a phase 2/3 randomised placebo-controlled crossover; the primary endpoints in the initial protocol were not met, but the open-label extension demonstrated durable improvements in knee-extensor strength, six-minute walk distance, and Barth syndrome-specific patient-reported outcome measures. This trial and its extension are the direct evidence base for the FDA approval.

MMPOWER-3 was the largest phase-3 trial in primary mitochondrial myopathy. It did not meet its primary six-minute-walk-distance endpoint. That result is important context: it argues against the idea that elamipretide is a general mitochondrial performance enhancer, and it defined the narrower Barth syndrome scope of the subsequent regulatory strategy.

The ReCLAIM programme in dry age-related macular degeneration (ReCLAIM-1 published; ReCLAIM-2 has reported readouts) has explored the compound in a very different tissue setting — the retinal pigment epithelium, whose mitochondrial density and cardiolipin content make it a plausible target. Results have been directionally supportive of a retinal-function signal but have not yet produced a definitive phase-3 confirmatory outcome.

Elamipretide is FDA-approved as Forzinity for Barth syndrome. This is a genuine pharmaceutical approval with a validated clinical development programme — TAZPOWER, TAZPOWER-2, and the mechanistic literature supporting the cardiolipin-targeting mode of action. The compound is one of very few in this catalog to hold an FDA approval as a peptide drug for a rare-disease indication.

The broader ambitions of the programme have had mixed outcomes. MMPOWER-3 in primary mitochondrial myopathy did not meet its primary endpoint; the acute cardiac programme (EMBRACE STEMI, MEND2) was discontinued after negative outcomes. The ReCLAIM programme in dry AMD has produced signal on retinal photoreceptor function but has not yet delivered a confirmatory phase-3 result.

The Barth syndrome community's engagement with the elamipretide programme has been unusually active. The initial FDA Complete Response Letter in 2020 prompted a significant patient-advocacy response that influenced the subsequent regulatory dialogue. That trajectory is part of the compound's history and worth understanding in context.